Charts

In this article, we’re going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought and Sold. Billionaire Steve Cohen is one of the most […]

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of November 30, 2023, the grant of restricted stock units (“RSUs”) covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to twelve new employees.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades ...

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

Is AbbVie (NYSE:ABBV) a drugmaker to wager on now? I believe it’s a very smart move to consider buying a few shares, especially in light of recent positive news about AbbVie. So, I am bullish on ABBV stock because there are identifiable catalysts that could lead to major share price appreciation. AbbVie is a large American drug manufacturer with a market cap that’s slightly over $250 billion. It’s often been considered a relatively safe company to invest in, and passive income seekers are certai

Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion.

The company announces a major deal worth over $10 billion.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Okta Inc (OKTA), where a total of 44,206 contracts have traded so far, representing approximately 4.4 million underlying shares. That amounts to about 178.7% of OKTA's average daily trading volume over the past month of 2.5 million shares..

Shares of ImmunoGen (IMGN), a biotechnology company focused on cancer treatments, surged Thursday afternoon on news that pharmaceutical giant AbbVie (ABBV) plans to acquire the company in a deal valued around $10 billion. Yahoo Finance's Diane King Hall and Josh Lipton break down the details of the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

In trading on Thursday, oil & gas refining & marketing shares were relative leaders, up on the day by about 2.5%. Leading the group were shares of REX American Resources, up about 34% and shares of Phillips 66 up about 5.2% on the day.

Jon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports!

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up ...

Shares of Titan Machinery Inc. (NASDAQ: TITN) moved lower during Thursday’s trading following weak quarterly results. Titan ...

Gainers Soligenix (NASDAQ:SNGX) stock moved upwards by 249.1% to $1.45 during Thursday's regular session. The company's market cap ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded up ...

AbbVie is buying rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment.

AbbVie Inc(NYSE: ABBV) has agreed to acquireImmunoGen Inc(NASDAQ: IMGN) and its flagship cancer therapy Elahere ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Soligenix stock is rising higher on Thursday with heavy trading of SNGX shares after getting FDA approval for a Phase 2 clinical trial. The post Why Is Soligenix (SNGX) Stock Up 285% Today? appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Minim stock is taking off with heavy trading of MINM shares on Thursday despite the company getting a delisting warning. The post Minim (MINM) Stock Soars 77% After Receiving Nasdaq Deficiency Notice appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

ImmunoGen stock was soaring Thursday following an announcement that biopharmaceutical company AbbVie has agreed to buy the cancer treatment developer for $10.1 billion. Under the terms of the sale agreement, AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share. The transaction is subject to shareholder and regulatory approval.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal. The post Why Is ImmunoGen (IMGN) Stock Up 81% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

The deal is a new bet by a big pharmaceutical company on a promising novel drug technology for directly targeting tumors.

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday. Shares of La-Z-Boy Incorporated ...

AbbVie (NYSE:ABBV) has announced an acquisition of Immunogen (NASDAQ:IMGN) that is expected to be completed 2024-H1. Under the terms of ...

Big pharma’s [$10.1 billion deal splash](https://www.wsj.com/business/deals/abbvie-to-buy-immunogen-for-more-than-10-billion-5e942e18?mod=business_lead_pos2) is giving biotech stocks a lift. AbbVie, which sells widely-used drugs like Humira and Skyrizi, said Thursday it plans to buy cancer drug developer ImmunoGen for $31.

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market ...

While the top- and bottom-line numbers for ImmunoGen (IMGN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ImmunoGen, Inc. (NASDAQ: IMGN) to AbbVie Inc. for $31.26 per share in cash is fair to ImmunoGen shareholders.

ImmunoGen's stock rocketed to the highest price seen in two decades after the biotechnology company announced an agreement to be acquired buy AbbVie in a cash deal valued at $10.1 billion.

AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The company said it will pay $31.26 in cash for each ImmunoGen share. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth.

Gainers Immunogen (NASDAQ:IMGN) shares moved upwards by 83.0% to $29.39 during Thursday's pre-market session. The company's market cap ...

(Reuters) -AbbVie will buy ImmunoGen for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to acquire a maker of promising "guided missile" cancer therapies as its top-selling treatment Humira faces newer rivals. ImmunoGen's Elahere belongs to a new class of treatments called antibody-drug conjugates (ADC) that precisely targets cancer cells, potentially reducing toxicity for other cells. With the deal, AbbVie is taking a meaningful step to close the gap from Humira's loss of exclusivity by "integrating ImmunoGen's potentially multi-billion dollar Elahere," BMO Capital Markets analyst Evan Seigerman said.

The deal, which prices ImmunoGen's stock at a 95% premium, could boost AbbVie's plans to expand into cancer drugs as its top-selling product Humira faces fierce competition.

AbbVie said on Thursday it will buy ImmunoGen for $10.1 billion, underscoring a growing interest from large drugmakers in a promising class of targeted cancer therapies. Through the deal, AbbVie gains Elahere that is approved for ovarian cancer patients who have received previous therapies, and is also being tested in earlier lines of treatment. Elahere is part of a new class of cancer drugs called antibody drug conjugates (ADC), which comprise a monoclonal antibody that precisely targets cancer cells and reduces toxicity of other cells.

AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs furthe

Among the best stocks to buy and watch, ovarian cancer treatment leader ImmunoGen is approaching an early buy point in today's stock market.

Investors exposed to the biotech sector have seen mixed results this year.

Breadth continued to improve on both the Nasdaq and the NYSE.

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Mid Cap Growth AlphaDEX Fund ETF (FNY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $70.58 per unit.

Investors eyeing a purchase of ImmunoGen, Inc. (IMGN) shares, but cautious about paying the going market price of $15.71/share, might benefit from considering selling puts among the alternative strategies at their disposal..

Analysts have provided the following ratings for Immunogen (NASDAQ:IMGN) within the last quarter: Bullish Somewhat ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference. The presentation is scheduled for November 15, 2023 at 9:30 am GMT / 4:30 am ET.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for mirvetuximab soravtansine (ELAHERE®) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares MSCI Transformational Changes ETF (ANEW), we found that the implied analyst target price for the ETF based upon its underlying holdings is $41.64 per unit.

Oppenheimerinitiated coverage onSutro Biopharma Inc(NASDAQ: STRO), representing around 200% potential ...

Upgrades According to B of A Securities, the prior rating for Clearway Energy Inc (NYSE:CWEN) was changed from Neutral to Buy. In the ...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC). The findings will be presented by Dr. Toon Van Gorp in an oral presentation today at the 24th Congress of the European Society of Gynaecological Oncology (ESGO) in Istanbul, Turkey.

Nvidia stock has tripled, but it's not No. 1 in 2023. Carvana has surged 1,001%, leading eight huge winners this year.

ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component ImmunoGen, Inc. (IMGN) was identified as having a larger market cap than the smaller end of the S&P 500, for example Newell Brands Inc (NWL), according to The Online Investor..